Wikisage, the free encyclopedia of the second generation, is digital heritage

Diacomit: Difference between revisions

From Wikisage
Jump to navigation Jump to search
mNo edit summary
m (todo)
Line 6: Line 6:


In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or clobazam<ref>Aras et al 2015</ref>
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or [[clobazam]]<ref>Aras et al 2015</ref>


==ATC==
==ATC==

Revision as of 04:25, 1 April 2016

Diacomit contains 250 mg stiripentol[1][2]

[3]


In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam[4]

ATC

http://www.whocc.no/atc_ddd_index/?code=N03AX17

  1. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf
  2. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.
  3. Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABAA-Receptor Channels
  4. Aras et al 2015